Skip to main content

opnurasib

Generic: Opnurasib

opnurasib: 6 clinical trials tracked.

opnurasib evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about opnurasib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trials (6)

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071·Phase 1/Phase 2·NVS
Recruiting

Primary endpoint: Number of participants receiving opnurasib as single agent or in combination with other study treatments

Interventionalopen40 targetStarted 2026-06Completion 2029-0915 sites · Belgium, Canada, China, Denmark…Novartis Pharmaceuticals

Neoadjuvant Platform Trial in Patients With Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

NCT05714891·Phase 2·NVS
Active, not recruiting

Primary endpoint: Identify promising neoadjuvant treatment regimens for NSCLC for later validation in randomized clinical trials, by evaluating major pathological response rates (MPR)

Interventionalopen4 targetStarted 2023-09Completion 2028-038 sites · CanadaCanadian Cancer Trials Group

KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843·Phase 2·NVS
Active, not recruiting
Interventionalopen95 targetStarted 2022-12Completion 2026-1245 sites · Argentina, Austria, Belgium, Brazil…Novartis Pharmaceuticals

KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249·Phase 1/Phase 2·NVS
Active, not recruiting

Primary endpoint: Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.

Interventionalopen74 targetStarted 2022-10Completion 2026-0913 sites · Belgium, France, Germany, Italy…Novartis Pharmaceuticals

A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075·Phase 3·NVS
Active, not recruiting

Primary endpoint: Progression free survival (PFS)

InterventionalRandomizedopen95 enrolledStarted 2022-06Completion 2026-0950 sites · Argentina, Australia, Canada, China…Novartis Pharmaceuticals

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188·Phase 1/Phase 2·NVS
Active, not recruiting

Primary endpoint: Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment

Interventionalopen344 targetStarted 2021-02Completion 2027-0138 sites · Australia, Belgium, Canada, China…Novartis Pharmaceuticals